Trial
NCT05444153
Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and Obesity
Phase IIIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Novo Nordisk A/S
Collaborators
—
Condition
Diabetes Mellitus, Type 2
Intervention
Semaglutide
Why stopped
Sponsor decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-11-14